REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX) and Sagimet Biosciences, Inc. Cla...

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Sagimet Biosciences, Inc. Class A (SGMT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on RegenXBio (RGNX) and Ansell (ANSLF). RegenXBio (RGNX) In a report...

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Ansell (OtherANSLF)

RegenXBio ( ($RGNX) ) has provided an update. On August 24, 2026, REGENXBIO reported that the U.S. Food and Drug Administration placed its Investig...

RegenXBio Faces RGX-121 Clinical Hold, Refocuses Pipeline

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on RegenXBio today and set a price target of $15.00. Stranahan covers the...

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Opus Genetics (IRD) and Reg...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RGNX	$9.66	+3.09%	1.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RGNX	$9.66	+3.1%	1.75M
3
4
5
6

RGNX

Get REGENXBIO Inc. Data in Excel

Get REGENXBIO Inc. Data in Excel